89 Results for "

lyn

" in MedChemExpress (MCE) Product Catalog:
Products (89)

89 Results for "lyn" in MCE Product Catalog:

  • Categories Recommended:
    More
47
47 Publications Verification
Art. -Nr.: HY-10234
CAS. Nr.: 379231-04-6
Reinheit:  99.92%
Synonyms: AZD0530
Target:  

Src Autophagy

Forschungsgebiete:  

Cancer

Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .
loading...
    loading...
47
47 Publications Verification
Art. -Nr.: HY-10234A
CAS. Nr.: 893428-72-3
Reinheit:  99.24%
Synonyms: AZD0530 difumarate
Target:  

Src

Forschungsgebiete:  

Cancer

Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
loading...
    loading...
38
38 Cited Publications
Art. -Nr.: HY-12067
CAS. Nr.: 841290-81-1
Reinheit:  96.70%
Target:  

Syk FLT3 Apoptosis

Forschungsgebiete:  

Inflammation/Immunology Cancer

R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
38
38 Cited Publications
Art. -Nr.: HY-11108
CAS. Nr.: 841290-80-0
Reinheit:  99.80%
Target:  

Syk FLT3 Apoptosis

Forschungsgebiete:  

Inflammation/Immunology Cancer

R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
24
24 Cited Publications
Art. -Nr.: HY-B0789
CAS. Nr.: 330161-87-0
Target:  

Src FAK Akt

Forschungsgebiete:  

Cancer

SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
loading...
    loading...
20
20 Cited Publications
Art. -Nr.: HY-13038A
CAS. Nr.: 901119-35-5
Reinheit:  99.70%
Synonyms: R788
Target:  

Syk FLT3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
20
20 Cited Publications
Art. -Nr.: HY-13038
CAS. Nr.: 1025687-58-4
Reinheit:  99.88%
Synonyms: R788Disodium
Target:  

Syk FLT3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
20
20 Cited Publications
Art. -Nr.: HY-13038B
CAS. Nr.: 914295-16-2
Reinheit:  99.51%
Synonyms: R788 disodium hexahydrate
Target:  

Syk FLT3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
14
14 Cited Publications
Art. -Nr.: HY-50868
CAS. Nr.: 859212-16-1
Synonyms: INNO-406; NS-187
Target:  

Bcr-Abl Src Apoptosis

Forschungsgebiete:  

Cancer

Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
loading...
    loading...
12
12 Cited Publications
Art. -Nr.: HY-15764
CAS. Nr.: 364042-47-7
Reinheit:  99.75%
Synonyms: RK-20449
Target:  

Src Apoptosis

Forschungsgebiete:  

Cancer

A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, has high selectivity towards the Src family. A 419259 shows inhibitory effect for Src, Lck and Lyn with IC50 of 9 nM, <3 nM and <3 nM, respectively .
loading...
    loading...
12
12 Cited Publications
Art. -Nr.: HY-15764A
CAS. Nr.: 1435934-25-0
Reinheit:  99.21%
Synonyms: RK 20449 trihydrochloride
Target:  

Src Apoptosis

Forschungsgebiete:  

Cancer

A 419259 trihydrochloride is a Src family kinases inhibitor with IC50s of 9 nM, 3 nM and 3 nM for Src, Lck and Lyn, respectively .
loading...
    loading...
8
8 Cited Publications
Art. -Nr.: HY-112852
CAS. Nr.: 1315330-17-6
Reinheit:  98.47%
Target:  

Src Apoptosis

Forschungsgebiete:  

Cancer

TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .
loading...
    loading...
7
7 Cited Publications
Art. -Nr.: HY-101923
CAS. Nr.: 2088939-99-3
Reinheit:  99.41%
Target:  

ULK Autophagy Apoptosis

Forschungsgebiete:  

Cancer

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) .
loading...
    loading...
7
7 Cited Publications
Art. -Nr.: HY-101923B
CAS. Nr.: 2310109-38-5
Reinheit:  99.55%
Target:  

ULK Autophagy Apoptosis

Forschungsgebiete:  

Cancer

LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC) .
loading...
    loading...
6
6 Cited Publications
Art. -Nr.: HY-59047
CAS. Nr.: 41964-07-2
Synonyms: MLR-1023
Target:  

Src

Forschungsgebiete:  

Metabolic Disease

Tolimidone is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM.
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-10209
CAS. Nr.: 790299-79-5
Reinheit:  99.95%
Synonyms: AB1010
Forschungsgebiete:  

Cancer

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-10209A
CAS. Nr.: 1048007-93-7
Reinheit:  99.51%
Synonyms: AB-1010 mesylate
Target:  

c-Kit PDGFR Src FGFR Apoptosis

Forschungsgebiete:  

Cancer

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-N2259
CAS. Nr.: 19431-84-6
Synonyms: (+)-Curcumenol
Curcumenol ((+)-Curcumenol) is a natural compound with oral efficacy, exhibiting an IC50 of 12.6 μM and a Ki of 10.8 μM against human CYP3A4. Curcumenol inhibits TNFα-induced phosphorylation/degradation of IκBα, phosphorylation/nuclear translocation of NF-κB p65, as well as the upregulation of MMP3, MMP9, MMP13, TRAF3, IL1RL1, TNFα and IL-1β. Curcumenol suppresses LPS-induced phosphorylation of Akt and p38 MAPK, as well as the production of pro-inflammatory mediators/proteins, and downregulates the SLC7A11/NF-κB/TGF-β pathway. Curcumenol binds to and inhibits the activation of Fyn and Lyn, blocks the function of downstream FcεRI signaling components, and reduces the release of allergic mediators/cytokines. Curcumenol upregulates the expression of KDM6B, and promotes chondrocyte proliferation and cartilage repair. Curcumenol induces ferroptosis and apoptosis, regulates the EMT process, and inhibits tumor growth and metastasis of triple-negative breast cancer. Curcumenol possesses anti-inflammatory, neuroprotective, antioxidant, antitumor, antiviral and hepatoprotective activities. Curcumenol can be used in research related to intervertebral disc degeneration, cancer, inflammation, central nervous system neurodegenerative diseases, allergic reactions and knee osteoarthritis .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-15749
CAS. Nr.: 898280-07-4
Reinheit:  99.64%
Forschungsgebiete:  

Endocrinology Cancer

XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-10185
CAS. Nr.: 867331-64-4
Reinheit:  98.96%
Target:  

Src VEGFR FGFR PDGFR

Forschungsgebiete:  

Inflammation/Immunology

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
loading...
    loading...